Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

20240814 HNRC drug microbial culture co-migration

ABSTRACT: Co-migration / spiking experiment to confirm the retention time of drug analogs detected in HNRC fecal samples with those in microbial cultures

INSTRUMENT(S): Q Exactive

ORGANISM(S): Na

SUBMITTER: Pieter Dorrestein

PROVIDER: MSV000095606 | MassIVE | Wed Aug 14 17:17:00 BST 2024

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

GNPS - 20240814 HNRC drug microbial culture co-migration

Project description:Co-migration / spiking experiment to confirm the retention time of drug analogs detected in HNRC fecal samples with those in microbial cultures

2024-08-14 | MSV000095606 | GNPS

20240930 HNRC sample HIV drug co-migration

Project description:Retention time check by co-migration of HIV drug standards with fecal samples from the HNRC cohort.

| MSV000095996 | MassIVE

GNPS - 20240930 HNRC sample HIV drug co-migration

Project description:Retention time check by co-migration of HIV drug standards with fecal samples from the HNRC cohort.

| MSV000095996 | GNPS

GNPS - HNRC sample co-migration with drug microbial incubations

Project description:HNRC sample spiked by drug microbial incubations to check retention time match of drug microbial metabolites

2024-10-02 | MSV000096013 | GNPS

Shifting the optimal stiffness for cell migration

Project description:Cell migration is central to many biological processes including embryonic development, wound healing, and cancer progression. Cell migration is sensitive to environmental stiffness, and many cell types exhibit a stiffness optimum at which migration is maximal. Here we present a cell migration simulator that predicts a stiffness optimum that can be shifted by altering the number of active molecular motors and clutches. This prediction is verified experimentally by comparing cell traction and F-actin retrograde flow for two cell types with differing amounts of active motors and clutches: embryonic chick forebrain neurons (ECFNs; optimum ~1 kPa) and U251 glioma cells (optimum ~100 kPa). In addition, the model predicts, and experiments confirm, that the stiffness optimum of U251 glioma cell migration, morphology, and F-actin retrograde flow rate can be shifted to lower stiffness by simultaneous drug inhibition of myosin II motors and integrin-mediated adhesions.

2017-05-23 | GSE95680 | GEO

HNRC HIV Fecal Samples Batch 7

Project description:UCSD HNRC Batch 7 Fecal samples of people with and without HIV

2025-06-11 | MSV000098125 | MassIVE

Project description:HNRC- Plasma microbiome

| PRJEB36408 | ENA

Fecal microbial infusion from lean donors increases insulin sensitivity in subjects with metabolic syndrome

Project description:Alterations in intestinal microbiota and intestinal short chain fatty acids profiles have been associated with the pathophysiology of obesity and insulin resistance. Whether intestinal microbiota dysbiosis is a causative factor in humans remains to be clarified We examined the effect of fecal microbial infusion from lean donors on the intestinal microbiota composition, glucose metabolism and small intestinal gene expression. Male subjects with metabolic syndrome underwent bowel lavage and were randomised to allogenic (from male lean donors with BMI<23 kg/m2, n=9) or autologous (reinfusion of own feces, n=9) fecal microbial transplant. Insulin sensitivity and fecal short chain fatty acid harvest were measured at baseline and 6 weeks after infusion. Intestinal microbiota composition was determined in fecal samples and jejunal mucosal biopsies were also analyzed for the host transcriptional response. Insulin sensitivity significantly improved six weeks after allogenic fecal microbial infusion (median Rd: from 26.2 to 45.3 μmol/kg.min, p<0.05). Allogenic fecal microbial infusion increased the overall amount of intestinal butyrate producing microbiota and enhanced fecal harvest of butyrate. Moreover, the transcriptome analysis of jejunal mucosal samples revealed an increased expression of genes involved in a G-protein receptor signalling cascade and subsequently in glucose homeostasis. Lean donor microbial infusion improves insulin sensitivity and levels of butyrate-producing and other intestinal microbiota in subjects with the metabolic syndrome. We propose a model wherein these bacteria provide an attractive therapeutic target for insulin resistance in humans. (Netherlands Trial Register NTR1776).

2020-10-28 | GSE30854 | GEO

HNRC_lithocholic_acid_n-acetylcadaverine_rt_matching

Project description:MS/MS fragmentation data of HNRC fecal samples acquired on Q Exactive - with chromatographic separation on a Phenomenex polar C18 column

2025-11-07 | MSV000099783 | MassIVE

Effect of morphine treatment on microbiome in the context of microbial transplant.

Project description:Morphine causes microbial dysbiosis. In this study we focused on restoration of native microbiota in morphine treated mice and looked at the extent of restoration and immunological consequences of this restoration. Fecal transplant has been successfully used clinically, especially for treating C. difficile infection2528. With our expanding knowledge of the central role of microbiome in maintenance of host immune homeostasis17, fecal transplant is gaining importance as a therapy for indications resulting from microbial dysbiosis. There is a major difference between fecal transplant being used for the treatment of C. difficile infection and the conditions described in our studies. The former strategy is based on the argument that microbial dysbiosis caused by disproportionate overgrowth of a pathobiont can be out-competed by re-introducing the missing flora by way of a normal microbiome transplant. This strategy is independent of host factors and systemic effects on the microbial composition. Here, we show that microbial dysbiosis caused due to morphine can be reversed by transplantation of microbiota from the placebo-treated animals.

2016-06-01 | E-MTAB-3723 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data